Reported 1 day ago
Johnson & Johnson is navigating significant challenges including ongoing lawsuits related to its talc products, potential revenue threats from patent expirations, and new drug price negotiation laws. Despite these hurdles, the company has a resilient business model, with strong revenue in its biopharma sector and promising growth prospects in medical technology, particularly through its Ottava robotic-assisted surgery device. Investors are advised to monitor the company's legal developments and its response to regulatory changes.
Source: YAHOO